SCHEDULE 13G/A: Others
8-K: Current report
10-Q/A: Quarterly report (Amendment)
10-Q: Q3 2024 Earnings Report
8-K: ENDRA Life Sciences Reports Third Quarter 2024 Financial Results and Provides a Business Update
NT 10-Q: Notice under Rule 12b25 of inability to timely file all or part of a form 10-Q or 10-QSB
8-K: Current report
8-K: Current report
DEFA14A: Others
DEF 14A: Definitive information statements
PRE 14A: Preliminary proxy statements relating to merger or acquisition
4/A: Statement of changes in beneficial ownership of securities (and amendment thereto)- UBS Group AG
3/A: Initial statement of beneficial ownership of securities (Amendment)- UBS Group AG
4: Statement of changes in beneficial ownership of securities-10% Owner UBS Group AG
3: Initial statement of beneficial ownership of securities-10% Owner UBS Group AG
8-K: Current report
8-K: ENDRA Life Sciences Reports Second Quarter 2024 Financial Results and Provides a Business Update
8-K: Current report
3: Initial statement of beneficial ownership of securities-Officer Jacroux Richard
10-Q: Q2 2024 Earnings Report